SCHEMBL17005959

SCHEMBL17005959

Cc1ccc(Cn2ccc(CN3CCN(C(=O)O)CC3)c(O)c2=O)cc1

nearest known ligand 0.66

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ VEGFA P15692 10/20 0.66
▸ EGLN1 Q9GZT9 10/20 0.66
▸ LMNA P02545 1/20 0.47
▸ SMN1; SMN2 Q16637 1/20 0.47
▸ TP53 P04637 1/20 0.47
▸ MAPT P10636 1/20 0.47
▸ MEN1 O00255 3/20 0.46
▸ KMT2A Q03164 3/20 0.46
▸ KDM4E B2RXH2 3/20 0.46
▸ POLB P06746 2/20 0.46
▸ ALDH1A1 P00352 2/20 0.46
▸ MAPK1 P28482 1/20 0.46
▸ FAAH O00519 1/20 0.46
▸ ATM Q13315 2/20 0.45
▸ L3MBTL1 Q9Y468 1/20 0.44
▸ NPSR1 Q6W5P4 1/20 0.43
▸ TDP1 Q9NUW8 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17005890 0.90 VEGFA (0.61) VEGFAEGLN1LMNAMEN1KMT2A
SCHEMBL14889521 0.89 VEGFA (0.72) VEGFAEGLN1LMNATP53MAPT
SCHEMBL20763926 0.89 VEGFA (0.83) VEGFAEGLN1LMNASMN1; SMN2MEN1
SCHEMBL17005850 0.89 VEGFA (0.60) VEGFAEGLN1LMNAMEN1KMT2A
SCHEMBL1770489 0.88 VEGFA (0.66) VEGFAEGLN1ALDH1A1FAAH
SCHEMBL17005946 0.88 VEGFA (0.66) VEGFAEGLN1LMNASMN1; SMN2KDM4E
SCHEMBL17005921 0.88 VEGFA (0.66) VEGFAEGLN1FAAH
SCHEMBL17005973 0.88 VEGFA (0.62) VEGFAEGLN1LMNAMAPTMEN1
SCHEMBL17005962 0.88 VEGFA (0.67) VEGFAEGLN1LMNAMAPTMEN1
SCHEMBL17005966 0.88 VEGFA (0.67) VEGFAEGLN1LMNASMN1; SMN2TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3107542-B1 PROCESS FOR PREPARING N-BENZYL-3-HYDROXY-4-SUBSTITUTED-PYRIDIN-2-(1H)-ONES AERPIO THERAPEUTICS INC (US) 2019-05-01 — — EP disclosed
US-9388135-B2 Process for preparing N-benzyl-3-hydroxy-4-substituted-pyridin-2-(1H)-ones AERPIO THERAPEUTICS, INC. (US) 2016-07-12 — — US disclosed
US-20150232425-A1 PROCESS FOR PREPARING N-BENZYL-3-HYDROXY-4-SUBSTITUTED-PYRIDIN-2-(1H)-ONES AERPIO THERAPEUTICS, INC. 2015-08-20 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150232425-A1 PROCESS FOR PREPARING N-BENZYL-3-HYDROXY-4-SUBSTITUTED-PYRIDIN-2-(1H)-ONES CYP4B1, CYP8B1, HPD VEGFA 4681/4885EGLN1 102/4885LMNA 954/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback